novo nordisk's semaglutide failed to slow alzheimer's disease progression fails of in highly anticipated trials, Nordisk says GLP-1 and neurodegeneration: lessons from

doi: 10.1038/sigtrans.2017.23 [DOI] [PMC free article] [PubMed] [Google Scholar] 96

Advantages: Non-invasive, cumulative depot effect in tissue (as per Hostynek data), suitable for daily use in skincare routines

While compounded semaglutide itself is not FDA-approved as a final product, the active ingredient is FDA-approved, and compounding pharmacies use FDA-regulated equipment and sterile techniques

I anticipated this as my BMI is not above their qualifying number

Second, lower levels of MTHF production mean that the methionine cycle slows down, which can lead to the accumulation of homocysteine

Diabetes 64 , 12351248 (2015)